​

Mowitz ME, Ayyagari R, Gao W, Zhao J, Mangili A, Sarda SP. Health care burden of bronchopulmonary dysplasia among extremely preterm infants. Front. Pediatr. 2019;7:510. doi:10.3389/fped.2019.00510

 

Tantawy AAG, El-Beshlawy A, Marzouk I, Bavdekar A, Qin Y, Mellgard B, Ben Turkia H. Results from a 12-month open-label phase 1/2 study of velaglucerase alfa in children and adolescents with type 3 Gaucher disease. J. Inborn Errors Metab. Screen. 2018;6:1-5 doi:10.1177/2326409818765564

 

Deegan P, Sasso FD, Giraldo P, Lau H, Panahloo Z, Zimran A. Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey. Blood Cells, Mol. Dis. 2018;68:218-225 doi:10.1016/j.bcmd.2016.10.014

 

Lau H, Belmatoug N, Deegan P, Goker-Alpan O, Schwartz IVD, Shankar SP, Panahlooh Z, Zimran A. Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher Outcome Survey. Blood Cells, Mol. Dis. 2018;68:226-231 doi:10.1016/j.bcmd.2016.10.003

 

Elstein D, Burrow AT, Charrow J, Giraldo P, Mehta A, Pastores GM, Lee H, Mellgard B, Zimran A. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease. Mol. Genet. Metab. 2017 120:111-115 doi:10.1016/j.ymgme.2016.08.005

​

Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Hak-Myung Lee, Crombez E, Pastores GM. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase. Mol. Genet. Metab. 2016;117:164-71. doi:10.1016/j.ymgme.2015.05.012